(-0.20%) 5 056.75 points
(-0.09%) 37 960 points
(-0.35%) 17 509 points
(-1.56%) $80.65
(-2.46%) $1.942
(0.16%) $2 306.60
(0.30%) $26.73
(1.23%) $959.85
(-0.07%) $0.936
(0.01%) $11.10
(0.12%) $0.801
(0.00%) $93.45
0.07% $ 42.33
Live Chart Being Loaded With Signals
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories...
Stats | |
---|---|
Объем за сегодня | 2.10M |
Средний объем | 1.07M |
Рыночная капитализация | 9.37B |
EPS | $0.550 ( 2024-04-29 ) |
Дата следующего отчета о доходах | ( $0.440 ) 2024-06-21 |
Last Dividend | $1.087 ( 2017-01-25 ) |
Next Dividend | $0 ( N/A ) |
P/E | 27.67 |
ATR14 | $0.0190 (0.04%) |
Объем Корреляция
Qiagen NV Корреляция
10 Самые положительные корреляции |
---|
10 Самые отрицательные корреляции |
---|
Вы знали?
Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).
Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.
Qiagen NV Корреляция - Валюта/Сырье
Qiagen NV Финансовые показатели
Annual | 2023 |
Выручка: | $1.97B |
Валовая прибыль: | $1.22B (62.23 %) |
EPS: | $1.540 |
FY | 2023 |
Выручка: | $1.97B |
Валовая прибыль: | $1.22B (62.23 %) |
EPS: | $1.540 |
FY | 2022 |
Выручка: | $2.14B |
Валовая прибыль: | $1.38B (64.65 %) |
EPS: | $1.920 |
FY | 2021 |
Выручка: | $2.25B |
Валовая прибыль: | $1.45B (64.43 %) |
EPS: | $2.25 |
Financial Reports:
No articles found.
Qiagen NV Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.00208 | 2002-12-26 |
Last Dividend | $1.087 | 2017-01-25 |
Next Dividend | $0 | N/A |
Payout Date | 2017-01-31 | |
Next Payout Date | N/A | |
# dividends | 2 | -- |
Total Paid Out | $1.089 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.39 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 4.37 | |
Div. Directional Score | 7.23 | -- |
Year | Amount | Yield |
---|---|---|
2002 | $0.00208 | 0.01% |
2003 | $0 | 0.00% |
2004 | $0 | 0.00% |
2005 | $0 | 0.00% |
2006 | $0 | 0.00% |
2007 | $0 | 0.00% |
2008 | $0 | 0.00% |
2009 | $0 | 0.00% |
2010 | $0 | 0.00% |
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $1.087 | 3.71% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
LOMA | Dividend Knight | 2023-06-30 | Quarterly | 2 | 5.23% | 8.53 |
PVL | Dividend King | 2023-11-15 | Monthly | 14 | 9.37% | 8.50 |
NCV | Dividend Royal | 2024-02-09 | Monthly | 22 | 7.68% | 8.50 |
MTR | Dividend Diamond | 2023-10-30 | Monthly | 39 | 10.10% | 8.50 |
SBR | Dividend Royal | 2023-11-14 | Monthly | 38 | 7.74% | 8.50 |
PDI | Dividend Royal | 2023-11-10 | Monthly | 13 | 7.86% | 8.50 |
ZTR | Dividend King | 2024-02-09 | Monthly | 37 | 8.35% | 8.50 |
ORC | Dividend Royal | 2023-11-29 | Monthly | 12 | 9.23% | 8.50 |
KIO | Dividend Royal | 2023-12-14 | Monthly | 12 | 7.05% | 8.50 |
NCZ | Dividend Royal | 2024-02-09 | Monthly | 22 | 7.79% | 8.50 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.174 | 1.500 | 6.53 | 9.79 | [0 - 0.5] |
returnOnAssetsTTM | 0.0558 | 1.200 | 8.14 | 9.77 | [0 - 0.3] |
returnOnEquityTTM | 0.0930 | 1.500 | -0.0782 | -0.117 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 1.990 | 0.800 | 5.05 | 4.04 | [1 - 3] |
quickRatioTTM | 1.458 | 0.800 | 6.13 | 4.90 | [0.8 - 2.5] |
cashRatioTTM | 0.619 | 1.500 | 7.67 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.251 | -1.500 | 5.82 | -8.74 | [0 - 0.6] |
interestCoverageTTM | 8.73 | 1.000 | 7.88 | 7.88 | [3 - 30] |
operatingCashFlowPerShareTTM | 2.08 | 2.00 | 9.31 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 1.340 | 2.00 | 9.33 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.402 | -1.500 | 8.39 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.643 | 1.000 | 2.62 | 2.62 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.237 | 1.000 | 7.26 | 7.26 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.300 | 1.000 | 9.45 | 9.45 | [0.2 - 2] |
assetTurnoverTTM | 0.321 | 0.800 | -1.191 | -0.953 | [0.5 - 2] |
Total Score | 10.09 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 27.46 | 1.000 | 7.33 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0930 | 2.50 | -0.0503 | -0.117 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 1.340 | 2.00 | 9.55 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 3.12 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 2.08 | 2.00 | 9.31 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.488 | 1.500 | -0.0789 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.234 | 1.000 | 6.66 | 0 | [0.1 - 0.5] |
Total Score | 4.37 |
Qiagen NV
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.
О Торговые сигналы
Данные торговые сигналы, представленные на этой странице, помогают определить, когда следует ПОКУПАТЬ или ПРОДАВАТЬ NA. Сигналы имеют задержку более 1 минуты. Пожалуйста, примите во внимание, что существует вероятность ошибки или неточностей в силу различных микро и макро факторов влияющих на фондовые рынки.
Данные тор“о”ые сигна“ы не являются определен“ыми, и getagraph.com не несет ответственности за какие-либо действия, предпринятые в от“ошении этих сигналов, как описано в Terms of Use. Сигналы основаны на широком спектре индикаторов технического анализа